On March 14, 2026, the CLIMACS study was presented at the European Association of Urology Annual Congress (EAU26) in London, revealing that the Melonga smartphone app — which teaches cognitive behavioral therapy, mindfulness, and physical exercises designed by urologists — doubled the average time to ejaculation in men with premature ejaculation, from 61 seconds to 125 seconds after 12 weeks of use.

Why It Matters

The Melonga study adds to a growing body of evidence that digital therapeutics can meaningfully treat sexual dysfunction — a category long dominated by pharmaceuticals. For the sex tech industry, clinically validated apps represent an expansion of the market beyond devices and consumables into software-based interventions that can scale globally with minimal marginal cost. The EAU26 presentation also legitimizes the approach within the urology community, potentially opening doors for insurance coverage and clinical referrals.

The study found that 22% of participants no longer met the clinical criteria for premature ejaculation by the end of the trial period. The app delivers structured therapeutic content including CBT techniques for managing performance anxiety, mindfulness exercises to increase body awareness during intercourse, and pelvic floor exercises. Unlike pharmaceutical interventions like delay sprays (Promescent) or SSRIs, the app targets the psychological and behavioral components of PE with zero side effects.

Premature ejaculation affects an estimated 20-30% of men globally, making it the most common male sexual dysfunction. Despite its prevalence, many men avoid seeking treatment due to embarrassment. Digital therapeutics like Melonga offer a private, accessible alternative to in-person therapy — a model already validated by apps like Mojo (targeting performance anxiety) and Blueheart (couples therapy). The CLIMACS study is notable for its clinical rigor, having been presented at a major urology congress rather than simply published as a company white paper.

The presentation follows a broader trend of digital therapeutics gaining clinical validation in sexual health, including the mylovia app's RCT for female sexual dysfunction (published in npj Digital Medicine) and Mojo's growing evidence base for erectile dysfunction-related anxiety.

Sources

Update — 2026-03-27

Initial entry — story first created.